2023 World Conference on Lung Cancer (Posters)-P2.05. SIPS as a Prognostic Biomarker within Performance Status in Advanced Lung Cancer Patients Treated with Pembrolizumab

P2.05. SIPS as a Prognostic Biomarker within Performance Status in Advanced Lung Cancer Patients Treated with Pembrolizumab - PDF(Abstract)

Back to course

Pdf Summary

This abstract presents a study on the relationship between performance status (PS) and the Scottish Inflammatory Prognostic Score (SIPS) in advanced non-small cell lung cancer (NSCLC) patients treated with pembrolizumab, an immunotherapy drug. The study aimed to identify prognostic tools to predict patient response to treatment. PS is a measure of a patient's functional status, while SIPS assesses a patient's systemic inflammatory status using neutrophil count and albumin level.<br /><br />The researchers analyzed a database of patients with NSCLC who received pembrolizumab at a cancer center in Scotland. The PS was divided into two groups: 0-1 or 2, representing patients considered suitable or uncertain for treatment, respectively. The SIPS score was calculated based on neutrophil count and albumin level, resulting in a score of 0, 1, or 2.<br /><br />The study found that SIPS significantly stratified survival outcomes regardless of PS scores. Patients with higher SIPS scores had lower median survival rates, with the median survival decreasing from 21.7 months, to 12.4 months, and then to 3.1 months for SIPS scores of 0, 1, and 2, respectively. This trend was observed in both PS groups. Patients with a PS of 2 and SIPS of 2 had a median survival of only 2.2 months.<br /><br />The results suggest that both PS and SIPS are easily accessible prognostic markers that can predict patient outcomes. The combination of a PS of 2 and SIPS of 2 was associated with poor survival and limited benefit from pembrolizumab treatment. The authors recommend further studies to validate these findings and guide treatment decisions for NSCLC patients.<br /><br />In summary, this study highlights the importance of PS and SIPS as prognostic markers in advanced NSCLC patients receiving pembrolizumab. These markers can help identify patients who are likely to benefit from treatment and improve realistic medicine treatment decision making.

Asset Subtitle

Samantha Low

Meta Tag

Speaker Samantha Low

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

performance status

Scottish Inflammatory Prognostic Score

advanced non-small cell lung cancer

NSCLC

pembrolizumab

prognostic tools

neutrophil count

albumin level

survival outcomes

treatment decisions